Updated 19 March 2020
Like most organizations around the world, Dendreon has been closely monitoring the COVID-19 pandemic and its impact on our patients, healthcare professionals and community. We continue to monitor and respond to this rapidly changing situation based on updates and recommendations from the CDC and local health officials, so please visit this page for updates.
To reach us directly with any questions, please email Corporate.Communications@Dendreon.com.
One of our chief priorities is to ensure the health and safety of our employees – not just for their own well-being and that of their families, but also to protect our ability to make and supply PROVENGE® (sipuleucel-T) to the patients who need this life-extending treatment.
To reduce the risk of virus transmission, we are taking measures to maximize “social distancing” by asking all Dendreon employees, including field-based associates, to work from home if they are able; minimize non-essential travel; and leverage digital tools and platforms in lieu of face-to-face meetings to ensure access to PROVENGE for patients.
Dendreon manufacturing facilities in Seal Beach, Calif., and Union City, Georgia, remain open and operational. As an added precaution, Dendreon has limited access to our manufacturing facilities to essential personnel only to reduce the risk of transmission. The entire Dendreon team remains fully committed to the delivery of PROVENGE treatments to our patients.
The PROVENGE manufacturing process requires logistical precision to ensure patient treatments are received and delivered on time. From beginning to end, we have just three days to collect a patient’s cells, manufacture PROVENGE and infuse the patient.
Dendreon relies on the airline industry to deliver this life-extending treatment. We are closely monitoring the impact of COVID-19 and, in anticipation of any disruption to commercial flights, have put contingency plans in place to protect/maintain the delivery of our patients’ treatments.
Dendreon works with a large apheresis network to collect the cells needed to manufacture PROVENGE, and they are working diligently to keep the apheresis center as safe as possible for our PROVENGE patients and their employees.
Many of our apheresis partners have taken additional measures to maintain patient safety in response to COVID‐19. These measures include: screening incoming patients regarding recent travel, and pre-screening to assess patients’ health and well-being.
We continue to engage public officials working to develop policies in response to COVID-19. We are advocating for policies that will protect men’s access to PROVENGE in an environment where travel is uncertain. We are also advocating for policies that support our skilled Dendreon team members to ensure they can care for themselves and loved ones while continuing to manufacture PROVENGE for men with advanced prostate cancer.
PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.